CLINICAL_TRIALS
trial_result
· 2019-12-09
Clinical Trial Update: Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease [Phase 3]
Summary
Phase III study of MLN0002 (300 mg) in Crohn's disease has completed; results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-12-09